NIH scientists identify early impact of Ebola virus on immune system

A new mouse model of early Ebola virus (EBOV) infection has shown National Institutes of Health (NIH) scientists and colleagues how early responses of the immune system can affect development of EBOV disease. The model could help identify protective immune responses as targets for developing human EBOV therapeutics.

Scientists from NIH's National Institute of Allergy and Infectious Diseases led the study with colleagues from the University of Washington and Columbia University.

The scientists analyzed signals that host cells use to alert the immune system to EBOV infection, and the immune system's responses. They focused on signaling events that begin within hours of a virus infection and involve the cellular mitochondrial antiviral signaling protein or MAVS.

The scientists already knew MAVS had a key anti-EBOV role, and in the current study examined it in an animal model for the first time. Many cell types produce MAVS, but MAVS produced by macrophages were found to be critical in controlling EBOV infection and to limiting the organ and tissue damage caused by EBOV.

In their experiments, macrophages coordinated the development of more advanced immune responses and the production of type I interferon, a compound with potent antiviral activity.

They also learned that EBOV could cause disease in mice by suppressing MAVS signaling and manipulating the interferon response.

With a goal of eventual drug development, the researchers are continuing their work to pinpoint the precise immune responses controlled through MAVS and to learn more about how EBOV sometimes delays immune signaling.

###

ARTICLE:

M Dutta et al. A systems approach reveals MAVS signaling in myeloid cells as critical for resistance to Ebola virus in murine models of infection. Cell Reports DOI: 10.1016/j.celrep.2016.12.069 (2017).

WHO:

Sonja Best, Ph.D., chief of NIAID's Innate Immunity and Pathogenesis Unit in the Laboratory of Virology, is available to comment on this study.

CONTACT:

To schedule interviews, please contact Ken Pekoc, (301) 402-1663, [email protected]

NIAID conducts and supports research–at NIH, throughout the United States, and worldwide–to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov/.

NIH…Turning Discovery Into Health®

Media Contact

Ken Pekoc
[email protected]
301-402-1663
@NIAIDNews

http://www.niaid.nih.gov

Comments
%d bloggers like this: